Edition:
United States

Nabriva Therapeutics PLC (NBRV.OQ)

NBRV.OQ on NASDAQ Stock Exchange Global Select Market

5.45USD
20 Feb 2018
Change (% chg)

$-0.05 (-0.91%)
Prev Close
$5.50
Open
$5.50
Day's High
$5.63
Day's Low
$5.44
Volume
28,319
Avg. Vol
61,398
52-wk High
$14.09
52-wk Low
$4.77

Revenue & Earnings Per Share

    Revenue* Earnings Per Share**
FY 2017 Sep '17 1.47 -0.791
Jun '17 1.05 -0.537
Mar '17 1.68 -5.596
FY 2016 Dec '16
Sep '16 0.97 -0.658
Jun '16 1.78 -0.570
Mar '16 1.42 -6.421
 
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars

Consensus Estimates Analysis

  # of Estimates Mean High Low 1 Year Ago
SALES (in millions)
Quarter Ending Mar-18 4 1.62 2.30 1.00 --
Quarter Ending Jun-18 4 1.62 2.40 0.80 --
Year Ending Dec-18 7 5.43 9.50 2.90 4.21
Earnings (per share)
Quarter Ending Mar-18 4 -0.57 -0.48 -0.63 --
Quarter Ending Jun-18 4 -0.56 -0.48 -0.63 --
Year Ending Dec-18 7 -2.29 -1.85 -2.86 -8.15
Sales and Profit Figures in US Dollar (USD);

Valuation Ratios

  Company industry sector
P/E Ratio (TTM) -- 180.40 35.76
P/E High - Last 5 Yrs. -- 281.08 46.66
P/E Low - Last 5 Yrs. -- 92.01 24.18
Beta -- 0.81 0.81
Price to Sales (TTM) 31.03 141.46 8.59
Price to Book (MRQ) 1.96 19.13 5.23
Price to Tangible Book (MRQ) 1.96 25.71 6.37
Price to Cash Flow (TTM) -- 120.28 26.13
% Owned Institutions 68.00 12.01 2.31

Dividends

  Company industry sector
Dividend Yield -- 0.29 1.50
Dividend Yield - 5 Year Avg -- 0.20 2.01
Dividend 5 Year Growth Rate -- 1.84 5.25
Payout Ratio(TTM) -- 8.47 44.77

Growth Rates

  Company industry sector
Sales (MRQ) vs Qtr. 1 Yr. Ago 51.18 43.81 9.62
Sales (TTM) vs TTM 1 Yr. Ago -18.11 45.25 7.31
Sales - 5 Yr. Growth Rate -- 32.48 10.20
EPS (MRQ) vs Qtr. 1 Yr. Ago -20.24 6.77 18.60
EPS (TTM) vs TTM 1 Yr. Ago -28.97 -- --
EPS - 5 Yr. Growth Rate -- 45.74 11.47
Capital Spending - 5 Yr. Growth Rate -- 41.90 14.75

Financial Strength

  Company industry sector
Quick Ratio (MRQ) -- 1.77 2.43
Current Ratio (MRQ) 7.22 6.14 3.39
LT Debt to Equity (MRQ) 0.22 16.68 11.95
Total Debt to Equity (MRQ) 0.22 18.86 15.32
Interest Coverage (TTM) -2.47 -165.00 38.67

Profitability Ratios

  Company industry sector
Gross Margin (TTM) -206.49 50.66 54.89
Gross Margin - 5 Yr. Avg. -- 55.48 52.59
EBITD Margin (TTM) -1,012.78 -- --
EBITD - 5 Yr. Avg -- -563.40 10.03
Operating Margin (TTM) -1,018.25 -589.85 2.96
Operating Margin - 5 Yr. Avg. -- -584.40 5.27
Pre-Tax Margin (TTM) -1,025.49 -559.39 3.78
Pre-Tax Margin - 5 Yr. Avg. -- -592.51 5.53
Net Profit Margin (TTM) -1,034.46 -554.46 0.26
Net Profit Margin - 5 Yr. Avg. -- -596.29 1.79
Effective Tax Rate (TTM) -- -0.06 22.06
Effective Tax Rate - 5 Yr. Avg. -- 17.84 24.20

Efficiency

  Company industry sector
Revenue/Employee (TTM) 110,237 23,379,765 824,372,705
Net Income/Employee (TTM) -1,140,356 -413,169 96,444,553
Receivable Turnover (TTM) 1.01 14.82 5.41
Inventory Turnover (TTM) -- 2.46 3.49
Asset Turnover (TTM) 0.06 0.39 0.90

Management Effectiveness

  Company industry sector
Return on Assets (TTM) -65.57 -0.92 10.73
Return on Assets - 5 Yr. Avg. -- -0.52 12.02
Return on Investment (TTM) -77.01 -0.52 13.59
Return on Investment - 5 Yr. Avg. -- 2.04 15.73
Return on Equity (TTM) -77.24 -3.30 15.20
Return on Equity - 5 Yr. Avg. -- -2.17 16.95
  1 Year 3 Year 5 Year
Sales % 72.07 -- --
EPS (TTM) % -7.80 -- --
Dividend % -- -- --
Note: Units in Millions of US Dollars

Performance for Nabriva Therapeutics PLC

Period %
Actual
% vs.
S&P 500
Rank In
Industry
Industry
Rank
4 Week -16.54 -14.16 17 61
13 Week -5.17 -10.50 38 91
26 Week -37.57 -44.58 13 87
52 Week -44.72 -52.51 20 88
YTD -8.03 -10.00 30 91
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.

Institutional Holders

% Shares Owned: 68.00%
# of Holders: 54
Total Shares Held: 24,951,800
3 Mo. Net Change: 78,670
# New Positions: 20
# Closed Positions: 13
# Increased Positions: 29
# Reduced Positions: 19
# Net Buyers: 10
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.